Clinical Trials Sponsored by Tocagen Inc

Total 35579 results

Tocagen Inc.

Completed

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Glioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Withdrawn

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Bladder Cancer
Tocagen Inc.

Terminated

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

Astrocytoma | Glioblastoma Multiforme | Gliomas, Malignant

United States
Tocagen Inc.

Terminated

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States, Korea, Republic of, Canada, Israel
Tocagen Inc.

Withdrawn

A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care (Toca7)

Newly Diagnosed High Grade Glioma (HGG)
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Toragen, Inc.

Recruiting

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

HPV Associated Cancers

United States
Covagen

Terminated

Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

Germany
Ocugen

Not yet recruiting

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) (DME)

Diabetic Macular Edema | Center Involved Diabetic Macular Edema
Ocugen

Recruiting

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

COVID-19

United States
Ocugen

Recruiting

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (OCU400)

Retinitis Pigmentosa | Leber Congenital Amaurosis

United States
Ocugen

Terminated

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease (oGVHD)

Graft vs Host Disease | Ocular Surface Disease | Graft Versus Host Disease | Ocular Graft vs Host Disease | Ophthalmic Solutions | oGVHD | Brimonidine Tartrate | Lubricant Eye Drops

United States
Icagen

Completed

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

Sickle Cell Disease | Sickle Cell Anemia

United States
Ocugen

Recruiting

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa (liMeliGhT)

Retinitis Pigmentosa

United States
Ocugen

Recruiting

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy (ArMaDa)

Geographic Atrophy

United States
Ocugen

Completed

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

Dry Eye

United States
Ocugen

Completed

Dry Eye Disease Study With Brimonidine

Dry Eye

United States
Icagen

Completed

Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma

Exercise Induced Asthma

United States
Zomagen Biosciences, Ltd

Completed

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore)

Cryopyrin Associated Periodic Syndrome

United States
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
Ocugen

Recruiting

Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease (GARDian)

Stargardt Disease

United States
Ocugen

No longer available

Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older

COVID-19

United States
Icagen

Completed

Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects

Atopic Asthma

United Kingdom
Oxagen Ltd

Completed

OC000459 Dose Finding Study in Hay Fever Sufferers.

Allergic Rhinitis

Austria
Oxagen Ltd

Completed

A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

Allergic Rhinitis

Austria
Oxagen Ltd

Completed

OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma

Mild to Moderate Persistent Asthma

Bulgaria, Russian Federation, Hungary, Romania, Ukraine, Poland
Oxagen Ltd

Completed

Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4

Healthy Volunteers

United Kingdom
Oxagen Ltd

Completed

Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

Asthma

Russian Federation
Oxagen Ltd

Completed

Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

Eosinophilic Esophagitis

Switzerland
Icagen
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Terminated

A Stratified Sickle Event Randomized Trial (ASSERT) (ASSERT)

Sickle Cell Disease

United States, France, United Kingdom, Brazil, Jamaica, Trinidad and Tobago
Icagen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy

Sickle Cell Disease | Sickle Cell Anemia

United States
Trevor Hansel
Oxagen Ltd

Completed

The Effects of OC000459 on Nasal Mediators

Allergic Rhinitis

United Kingdom
Sandeep Jain, MD
Ocugen

Terminated

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

Dry Eye | Meibomian Gland Dysfunction | Ocular Graft vs Host Disease

United States
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
Oxagen Ltd
King's College Hospital NHS Trust; Medicines Evaluation Unit, Manchester, UK

Completed

OC000459 Bronchial Allergen Challenge

Bronchial Asthma

United Kingdom
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Cedars-Sinai Medical Center
National Cancer Institute (NCI); VA Long Beach Healthcare System; Nonagen Bioscience...

Recruiting

A Diagnostic for the Early Detection of Bladder Cancer

Bladder Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
IGC Pharma LLC

Completed

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Dementia of Alzheimer Type

Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Completed

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Hematologic Malignancies | Malignant Solid Tumor

United States
IGC Pharma LLC

Recruiting

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

Aggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive Outburst

United States, Canada, Puerto Rico

Clinical Trials Sponsored by Tocagen Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations